|
The influence of busulfan plasma concentration on outcome of bone marrow transplantation was examined in 10 patients transplanted. All patients received the same regiment of busulfan, 4㎎/㎏/day orally. Plasma concentrations of busulfan during the administration were measured at sampling time. As a result, means of half life, Kd, first-dose AUC, Cpss_(av??), Cpss_(peak) and Cpss_(trough) were 2.184hr, 0.352hr^(-1), 8,876ng·h/㎖, 2,548ng/㎖, 4,161ng/㎖ and 935ng/㎖, respectively. Of patients with high Cpss_(trough) (>1,000ng/㎖), three patients developed increased liver function test value. One patient (Cpss-(trough) 2,002ng/㎖) developed veno-occlusive disease. There was no significant association of plasma concentration with graft vs host disease, infection, regimen-related toxicity. We assume that high Cpss_(trough) may be associated with an increase risk of veno-occlusive disease.
|